Hospira racks up higher Q1 sales; FDA OKs Novartis' Zykadia; Otsuka takes TB drug to EU;

@FiercePharma: Sources: Bayer offers animal health biz, cash for Merck's OTC unit. News | Follow @FiercePharma

@TracyStaton: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Story | Follow @TracyStaton

@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Advair slide, China woes drop-kick Glaxo profits in Q1. Article | Follow @CarlyHFierce

> Generic injectable drug specialist Hospira ($HSP) reported a 6.3% rise in Q1 sales of just over $1 billion compared to adjusted net sales in the same quarter a year ago. Release

> Novartis ($NVS) got FDA approval for Zykadia (ceritinib) for treating patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Release

> Endo Health Solutions ($ENDP) has agreed to buy Mexico's Somar, a privately owned specialty pharma company, for an undisclosed amount. Report

> Franklin, TN-based Rare Disease Therapeutics has gotten FDA approval for Purixan (mercaptopurine) 20 mg/mL oral suspension, a liquid form of an established treatment for patients with Acute Lymphoblastic Leukemia (ALL). Release

> Japan's Otsuka Pharmaceutical has been granted EU approval for its delamanid tuberculosis drug, for treating pulmonary multidrug-resistant tuberculosis in adult patients. Story

> Italian pharmaceutical company Rottapharm Madaus, which is controlled by the Rovati family in Italy, has filed to be listed on the stock exchange in Milan. Report

Medical Device News

@FierceMedDev: The latest FierceDiagnostics is out, with scoops on Quest Diagnostics, Roche, VC funding and more. Read | Follow @FierceMedDev

@VarunSaxena2: Zogenix retaining rights to DosePro delivery technology in transaction with Endo. Story via FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI here's yesterday's issue of FierceBiotech Research (stories on MERS, Alzheimer's and HIV). Read | Follow @EmilyWFierce

@MichaelGFierce: Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. More via FierceDrugDelivery | Follow @MichaelGFierce

> FDA deems faulty HeartWare tech potentially deadly. News

> Medtronic reveals positive data from new TAVR study for extreme-risk patients. More

> Teleflex teams up with Intuitive on next-gen da Vinci tech. Article

Biotech News

@FierceBiotech: GSK ups odds on heart drug hopeful with a changeup in endpoints. Story | Follow @FierceBiotech

@JohnCFierce: So after years of watching U.K. R&D get carved up like a cooked goose, lawmakers now want to probe the Pfizer deal? More | Follow @JohnCFierce

@DamianFierce: This list, via @JacobEPVantage, is like looking at an old yearbook. Qnexa was cute. I don't even recognize Sovaldi. Report | Follow @DamianFierce

@EmilyMFierce: ICYMI here's yesterday's issue of FierceBiotech Research: Report | Follow @EmilyMFierce

> Biopsy snafu torpedoes PhII prostate cancer data for Nymox. More

> Sanofi's MS team rebuilds its case for the FDA-rejected MS drug Lemtrada. Story

> Regeneron R&D chief's compensation shrinks, but still tops the chart. Article

Drug Delivery News

> Zogenix retaining rights to DosePro delivery technology in transaction with Endo. News

> Oramed's oral insulin PhIIa details show a compromised study, and shares continue to fall. Report

> Civitas announces positive results from Phase II inhaled levodopa trial. Story

> Cynapsus makes progress on sublingually delivered Parkinson's therapy. More

> Johns Hopkins team delivers cancer-killing DNA to mouse brains with nanovehicles. Article

> Imaging technique maps transdermal drug migration. Item

Diagnostics News

> Seattle firm attracts $47.25M for blood test that confirms benign lung nodules. News

> A certain protein marks tumors that will resist Astellas' prostate cancer drug Xtandi. Story

> Two new osteoarthritis biomarkers eyed for predictive Dx. More

> Quest to unveil new epilepsy tests in the wake of disappointing Q1 numbers. Article

> Roche-Evotec biomarker collaboration scores its first big milestone. Story

Pharma Marketing News

> Merck recruits ex-Law & Order star for new diabetes campaign. News

> With Big Pharma mergers in the works, whose SG&A costs look ripe for cutting? Report

> Sanofi bucks unit-sale trend with plan to unload $7B worth of older products. Item

> It's make-or-break time for GSK's new sales model as Anoro hits the U.S. market. Story

> GlaxoSmithKline dispatches sales and marketing team to clean up in China. More

> Simplify the DTC roll call of side effects? Yes, please, drugmakers tell FDA. Article

And Finally... The Andhra Pradesh High Court in India has put a temporary hold on Sun Pharmaceutical's $3.2 billion purchase of Ranbaxy Laboratories, while it considers a case brought by investors alleging insider trading ahead of the announcement. Story

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…